Company Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.
The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
Immatics N.V. is headquartered in Tübingen, Germany.
| Country | Germany |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 535 |
| CEO | Dr. Harpreet Singh Ph.D. |
Contact Details
Address: Paul Ehrlich-strasse 15 Tubingen, 2M 72076 Germany | |
| Phone | 49 7071 5397 700 |
| Website | immatics.com |
Stock Details
| Ticker Symbol | IMTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001809196 |
| CUSIP Number | N44445109 |
| ISIN Number | NL0015285941 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harpreet Singh Ph.D. | Chief Executive Officer, MD, Member of Management Board and Executive Director |
| Dr. Toni Weinschenk Ph.D. | Co-Founder and Chief Innovation Officer |
| Arnd Christ MBA | Chief Financial Officer |
| Steffen Walter Ph.D. | Chief Operations Officer |
| Edward A. Sturchio J.D. | General Counsel and Secretary |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer |
| Cedrik M. Britten M.D. | Chief Medical Officer |
| Jordan Silverstein | Head of Strategy |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting and Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 6-K | Report of foreign issuer |
| Mar 21, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 22, 2024 | 6-K | Report of foreign issuer |
| Jan 19, 2024 | 424B5 | Filing |
| Jan 17, 2024 | 424B5 | Filing |
| Nov 14, 2023 | 6-K | Report of foreign issuer |